1-(3-甲基-3-苯基丁基)-4-(2-(3-吡啶基)噻唑烷-4-基羰基)哌嗪富马酸盐 | 131888-54-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(3-甲基-3-苯基丁基)-4-(2-(3-吡啶基)噻唑烷-4-基羰基)哌嗪富马酸盐
• 英文名称: 1-(3-methyl-3-phenylbutyl]-4-[2-(pyridin-3-yl)thiazolidin-4-ylcarbonyl]piperazine fumarate
• 英文别名: 1-(3-methyl-3-phenylbutyl]-4-[2-(3-pyridyl)thiazolidin-4-ylcarbonyl]piperazine fumarate；1-(3-Methyl-3-phenylbutyl)-4-(2-(3-pyridyl)thiazolidin-4-ylcarbonyl)piperazine fumarate；(E)-but-2-enedioic acid;[4-(3-methyl-3-phenylbutyl)piperazin-1-yl]-(2-pyridin-3-yl-1,3-thiazolidin-4-yl)methanone
• CAS: 131888-54-5
• 化学式: C₄H₄O₄*C₂₄H₃₂N₄OS
• 分子量: 540.684
• InChiKey: LBPPBLYOJCIZRW-WLHGVMLRSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.01
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  148
• 氢给体数：
  3
• 氢受体数：
  9

制备方法与用途

生物活性

YM-264 是一种有口服活性的、血小板活化因子 (PAF) 的有效选择性拮抗剂，其在兔子血小板膜上的 pKi 值为 8.85。

靶点

pKi: 8.85 (PAF, rabbit platelet membranes).

体外研究

The anti-platelet-activating factor effect of YM-264 is examined in vitro. YM-264 inhibits [ ³ H] platelet-activating factor binding to rabbit platelet membranes with a pK _i value of 8.85. YM-264 inhibits the platelet-activating factor-induced human, rabbit and guinea-pig platelet aggregation with pA2 values of 8.68, 8.33 and 8.14, respectively.

体内研究

There are no significant differences in baseline airway responsiveness between control and YM-264 treated groups. Airway hyperresponsiveness induced by antigen exposure is significantly inhibited by the administration of YM-264. The baseline Rrs is 0.40 (0.02) cm H ₂ O/mL/s in the control group (n=6). In the YM-264 treated groups, the baseline Rrs is 0.39 (0.01) and 0.36 (0.01) cm H ₂ O/mL/s at a doses of 1 mg/kg (n=5) and 3 mg/kg (n=6), respectively. The Rrs during the IAR significantly increase from baseline to 0.92 (0.10) cm H ₂ O/mL/s in control (p=0.0002), 0.81 (0.12) in YM-264 1 mg/kg (p=0.01), and 1.06 (0.29) in YM-264 3 mg/kg (p=0.048). Reelevation of Rrs in the late phase is observed in the control group after antigen challenge. At this phase, Rrs significantly increase to 0.72 (0.10) cm H ₂ O/mL/s (p=0.0101) from the baseline (0.40) at 6 h after the exposure of antigen. In contrast, YM-264 at the doses of 1 and 3 mg/kg show significant inhibition of reelevation of Rrs as compared with control. YM-264 inhibit the eosinophil infiltration dose dependently.

反应信息

• 作为产物：
  描述：

  1-(3-Methyl-3-phenylbutyl)-4-[2-(3-pyridyl)thiazolidin-4-ylcarbonyl]piperazine 、 富马酸 在 乙醇 作用下， 以 乙醇 为溶剂， 反应 26.0h， 以to give 1.08 g of 1-(3-methyl-3-phenylbutyl]-4-[2-(3-pyridyl)thiazolidin-4-ylcarbonyl]piperazine fumarate的产率得到1-(3-甲基-3-苯基丁基)-4-(2-(3-吡啶基)噻唑烷-4-基羰基)哌嗪富马酸盐
  参考文献：
  名称：

  Saturated heterocyclic carboxamide derivatives

  摘要：

  以下是通式（I）的饱和杂环羧酰胺衍生物及其盐，具有血小板活化因子（PAF）拮抗活性。##STR1##

  公开号：

  US04987132A1

文献信息

• MASEH, TOSIYASU;XARA, XIROSI;SUDZUKI, TAKEHMORO;NAGAOKA, XITOSI;TAKAXASI,+
  作者：MASEH, TOSIYASU、XARA, XIROSI、SUDZUKI, TAKEHMORO、NAGAOKA, XITOSI、TAKAXASI,+

  DOI：——

  日期：——
• US4987132A
  申请人：——

  公开号：US4987132A

  公开（公告）日：1991-01-22